E Fund Management Co. Ltd. Has $401,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

E Fund Management Co. Ltd. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,922 shares of the biopharmaceutical company’s stock after buying an additional 2,514 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Pfizer were worth $401,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC boosted its stake in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after purchasing an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new position in Pfizer during the fourth quarter worth $255,000. KLCM Advisors Inc. increased its position in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares during the last quarter. Finally, Farmers Trust Co. raised its stake in shares of Pfizer by 2.0% during the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.3 %

Shares of NYSE PFE traded down $0.09 during trading on Thursday, hitting $28.18. The stock had a trading volume of 46,638,398 shares, compared to its average volume of 43,578,344. The firm has a fifty day moving average of $26.94 and a two-hundred day moving average of $28.12. The company has a market capitalization of $159.57 billion, a PE ratio of -469.59, a PEG ratio of 1.17 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.96%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of a number of research reports. Morgan Stanley upped their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $36.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.